Acellular pertussis vaccine for adolescents

Carvalho, Aroldo P. de; Pereira, Eliane Mara Cesário

doi:10.2223/jped.1491

Cited by 14 publications

(7 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…47,48 The classical vaccine (DPT) has cellular components that can trigger the development of adverse reactions; however, it is recommended in patients with RD, even those on immunosuppressive therapy. 49,50 Four studies including 95 patients and 125 healthy controls show the immunogenicity of the TT or TD vaccines. High antibody concentrations against tetanus (3 studies) and diphtheria (1 study) were found.…”

Section: Diphteria-pertussis-tetanus Vaccinementioning

confidence: 99%

Current information about vaccination practice in pediatric rheumatic diseases and recommendations for future applications

Açarı

Ünsal

2017

Turk J Pediatr

View full text Add to dashboard Cite

Section: Diphteria-pertussis-tetanus Vaccinementioning

confidence: 99%

Current information about vaccination practice in pediatric rheumatic diseases and recommendations for future applications

Açarı

Ünsal

2017

Turk J Pediatr

View full text Add to dashboard Cite

“…7,60 As for the pertussis fraction, the classical vaccine (DPT) has cellular components capable of triggering the development of adverse reactions, it is also not specifically contraindicated in patients with rheumatic diseases, even those on immunosuppressive therapy (evidence A). 81,82 Patients with an incomplete vaccine schedule should be oriented to complete it normally; in those who completed the schedule, a booster dose in adolescence is recommended, since, along with infants and adults, this age group is one of the most affected by whooping cough (evidence C). 83 Commercial presentations of DTaP with 3 and 5 pertussis components, with similar clinical efficacy, are available (evidence A).…”

Section: Acellular Triple (Dtap/tdap) and Double (Tt/td) Vaccinesmentioning

confidence: 99%

Consenso de imunização para crianças e adolescentes com doenças reumatológicas

Silva¹,

Terreri²,

Barbosa³

et al. 2009

Rev. Bras. Reumatol.

View full text Add to dashboard Cite

Incidence of infectious diseases is higher in children and adolescents with rheumatic diseases than in the general population due to disease activity, possible immune deficiency secondary to the disease itself, or the use of immunosuppressive drugs. Vaccination is effective in reducing morbidity and mortality in those patients. The objective of this study was to establish an evidence-based consensus on the efficacy and safety of vaccination in children and adolescents with rheumatic diseases. Passive immunization of patients and guidelines for people who live with immunosuppressed patients were also included. The 32 pediatric rheumatologists of the Rheumatology Department of the Pediatrics Society of São Paulo, (SPSP, from the Portuguese), São Paulo, SP, Brazil, and/or the Commission on Pediatrics Rheumatology of the Brazilian Society of Rheumatology are responsible for this consensus; some of those professionals are involved on research and scientific publications in this field. The words efficacy and/or safety of different vaccines in children and adolescents with rheumatologic diseases were searched in Medline and Scielo data bases from 1966 to March 2009, including reviews, controlled studies, and case reports. The degree of recommendation and the scientific evidence of the studies were classified in four levels for each vaccine. As a rule, inactive and protein components vaccines are safe for patients with rheumatologic diseases, even in the presence of immunosuppressive therapy. However, live attenuated vaccines are, in general, contraindicated for immunosuppressed patients.

show abstract

“…Studies in progress have demonstrated that is possible to produce for each 10 or 20 doses of the traditional wP or of the Plow, one dose of the aP vaccine. This vaccine may be used in children who present contraindications for vaccination with wP, or in adolescents 3 , and adults, in which the cellular component is not indicated.…”

Section: Dtp Low -A New Cellular Pertussis Vaccinementioning

confidence: 99%

Acellular and "low" pertussis vaccines: adverse events and the role of mutations

Higashi

Luna²,

Precioso³

et al. 2009

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

SUMMARYObjective: to discuss the current PAHO recommendation that does not support the substitution of traditional cellular DTP vaccine by acellular DTP, and the role of mutations, in humans, as the main cause of rare adverse events, such as epileptic-like convulsions, triggered by pertussis vaccine.Data review: the main components related to toxic effects of cellular pertussis vaccines are the lipopolysaccharide of bacterial cell wall and pertussis toxin. The removal of part of lipopolysaccharide layer has allowed the creation of a safer cellular pertussis vaccine, with costs comparable to the traditional cellular vaccine, and which may be a substitute for the acellular vaccine. Conclusion:The new methodology introduced by Instituto Butantan allows for the development of a new safer pertussis vaccine with low LPS content (Plow), and the use of the lipopolysaccharide obtained in the process in the production of monophosphoryl lipid A. This component has shown potent adjuvant effect when administered together with influenza inactivated vaccine, making possible to reduce the antigen dose, enhancing the production capacity and lowering costs.

show abstract

Acellular pertussis vaccine for adolescents

Cited by 14 publications

References 46 publications

Current information about vaccination practice in pediatric rheumatic diseases and recommendations for future applications

Current information about vaccination practice in pediatric rheumatic diseases and recommendations for future applications

Consenso de imunização para crianças e adolescentes com doenças reumatológicas

Acellular and "low" pertussis vaccines: adverse events and the role of mutations

Contact Info

Product

Resources

About